ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services   Dublin, Ireland, and Montreal, Canada, 01 October 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’),.

CRISPR/Cas9 Prime Editing is a novel gene editing technique that utilizes a modified Cas9 protein to introduce mutations in the genome with a higher degree of safety and complexity. This technique represents an evolution in the CRISPR/Cas9 system that enables researchers to more safely create complex genetic changes than using.

ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications   Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult.